Expert Interviews

Muthiah Vaduganathan, MD: Key Takeaways from Sotagliflozin Data

November 21, 2020

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

Deepak Bhatt, MD: STRENGTH, REDUCE-IT, and DHA

November 17, 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.

Deepak Bhatt, MD: Sotagliflozin and Phase 3 Data from AHA 2020

November 17, 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward.

John McMurray, MD: DAPA-CKD and Cardiorenal Protection

November 14, 2020

Professor John McMurray discusses DAPA-CKD and what insights it provides into the cardiorenal protection seen with dapagliflozin (Farxiga) use in the landmark trial.

Should Men and Women with HFpEF be Treated Differently?

November 14, 2020

Professor John McMurray offers insight into a discussion he led at AHA 2020 exploring the notion that treatment of men and women with heart failure with preserved ejection fraction should be approached differently.

George Bakris, MD: Improving SGLT2 Inhibitor Prescribing Practices

November 11, 2020

George Bakris, MD, discusses an AHA 2020 study that estimated the number of diabetics in the US that were considered eligible for receiving a prescription for an SGLT2 inhibitor.

Inside Cardiology: Bempedoic Acid

November 09, 2020

Practical Cardiology's Chief Advisory Board member Dr. Guy Mintz and a principal investigator from the CLEAR program discuss bempedoic acid and how they envision it fitting into treatment algorithms going forward.

Tsuyoshi Kaneko, MD: Perspective on TAVR Data at TCT Connect 2020

October 20, 2020

Practical Cardiology advisory board member Tsuyoshi Kaneko, MD, reflects on 3 studies examining topics related to TAVR from late-breaking sessions at TCT Connect 2020.

Muthiah Vaduganathan, MD: Prescribing Patterns of SGLT2 Inhibitors, GLP-1 Receptor Agonists

October 12, 2020

Muthiah Vaduganathan, MD, MPH, of Brigham and Women's discusses the barriers to preventing optimal prescribing practices for SGLT2 inhibitor and GLP-1 receptor agonist therapies.

Muthiah Vaduganathan, MD: Use of Diuretics, RAAS Inhibitors with SGLT2 Inhibitors

October 07, 2020

A cardiologist from Brigham and Women's Hospital discusses prescribing SGLT2 inhibitors to patients already receiving or with an indication for diuretics or RAAS inhibitors.